They observed multiple TET2 mutations (≥ 2) in 57% of AITL and PTCL-TFH cases; similar to our finding that nearly half of TET2-mutated cases had multiple mutations. This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.